Entasis Therapeutics Holdings Inc.

ETTXCIK 0001724344 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 2, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0013

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Entasis Therapeutics Holdings Inc.

Name	Roles	Filings
Tommasi Ruben	Officer	2
Innoviva Strategic Opportunities LLC	Director10% Owner	1
Innoviva, Inc.	10% Owner	1
Triola Anna Diaz	Officer	1
Wagner Kristie Ann	Officer	1

Showing 11-15 of 15

Per pagePrevPage 3 of 3

All filings

25 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Feb 15, 2022	Berger Heather A. Director	Holdings only	-	-	-
Feb 15, 2022	Meek David D. Director	Holdings only	-	-	-
Feb 15, 2022	Mayer Howard Director	Holdings only	-	-	-
Feb 15, 2022	Mueller John Patrick Chief Development Officer	Holdings only	-	-	-
Feb 15, 2022	Perros Manoussos President and CEO	Holdings only	-	-	-

Showing 6-10 of 25

Per pagePrevPage 2 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value

Entasis Therapeutics Holdings Inc.

Annual report (10-K)

Top insiders

All filings

External resources

Permalink